BRPI0717834B8 - purificação de polissacarídeos tipo 3 de streptococcus pneumoniae - Google Patents
purificação de polissacarídeos tipo 3 de streptococcus pneumoniaeInfo
- Publication number
- BRPI0717834B8 BRPI0717834B8 BRPI0717834A BRPI0717834A BRPI0717834B8 BR PI0717834 B8 BRPI0717834 B8 BR PI0717834B8 BR PI0717834 A BRPI0717834 A BR PI0717834A BR PI0717834 A BRPI0717834 A BR PI0717834A BR PI0717834 B8 BRPI0717834 B8 BR PI0717834B8
- Authority
- BR
- Brazil
- Prior art keywords
- lysate
- methods
- precipitation
- cause
- aggregation
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title abstract 3
- 229920001282 polysaccharide Polymers 0.000 title abstract 3
- 239000005017 polysaccharide Substances 0.000 title abstract 3
- 241000193998 Streptococcus pneumoniae Species 0.000 title abstract 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title 1
- 239000006166 lysate Substances 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 6
- 238000001556 precipitation Methods 0.000 abstract 3
- 230000006920 protein precipitation Effects 0.000 abstract 3
- 230000002776 aggregation Effects 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 2
- 238000010438 heat treatment Methods 0.000 abstract 2
- 238000010979 pH adjustment Methods 0.000 abstract 2
- 230000004845 protein aggregation Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
métodos para a redução ou remoção de impurezas protéicas de um lisado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotlpo 3 a presente invenção refere-se a métodos aperfeiçoados para a redução ou remoção de impurezas protéicas de um complexo lisato ou centrado celular de streptococcus pneumoniae que compreende polissacarídeos sorotipo 3, envolvendo etapas que referem-se a aquecimento pós-lise ou ajuste de ph. em certos métodos, o lisado é aquecido por um tempo e a uma temperatura suficiente para desnaturar proteínas presentes no lisado e provocar sua agregação e precipitação. em uma modalidade, o lisado é aquecido a pelo menos 60°c por pelo menos 30 minutos para causar agregação e precipitação de proteínas, mais particularmente cerca de 60°c a cerca de 70°c por cerca de 30 a cerca de 50 minutos, e ainda mais particularmente a cerca de 65°c por cerca de 40 minutos. em outros métodos, o ph do lisado ou centrado é elevado para pelo menos 8,0 para aperfeiçoar capacidade de filtração, mais particularmente cerca de 8,0 a 8,4, e ainda mais particularmente cerca de 8,2. em métodos adicionais, etapas de aquecimento e ajuste de ph são combinadas para provocar a agregação e precipitação de proteínas, bem como para aperfeiçoar capacidade de filtração dos lisados ou centrados. em outros métodos, o ph do lisado ou centrado é baixado para cerca de 3,0 a cerca de 5,0 para causar agregação e precipitação de proteínas. tais métodos permitem a produção de lisados ou centrados que contêm polissacarídeos sorotipo 3 substancialmente purificados.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122019021950A BR122019021950B8 (pt) | 2006-10-10 | 2007-10-09 | métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85066506P | 2006-10-10 | 2006-10-10 | |
| PCT/US2007/080768 WO2008045852A2 (en) | 2006-10-10 | 2007-10-09 | Purification of streptococcus pneumoniae type 3 polysaccharides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0717834A2 BRPI0717834A2 (pt) | 2014-06-10 |
| BRPI0717834B1 BRPI0717834B1 (pt) | 2020-05-19 |
| BRPI0717834B8 true BRPI0717834B8 (pt) | 2021-05-25 |
Family
ID=39156240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717834A BRPI0717834B8 (pt) | 2006-10-10 | 2007-10-09 | purificação de polissacarídeos tipo 3 de streptococcus pneumoniae |
| BR122019021950A BR122019021950B8 (pt) | 2006-10-10 | 2007-10-09 | métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122019021950A BR122019021950B8 (pt) | 2006-10-10 | 2007-10-09 | métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7659090B2 (pt) |
| JP (1) | JP5260531B2 (pt) |
| KR (1) | KR101467002B1 (pt) |
| CN (2) | CN101522906B (pt) |
| AT (1) | ATE473289T1 (pt) |
| AU (1) | AU2007307800C1 (pt) |
| BR (2) | BRPI0717834B8 (pt) |
| CA (1) | CA2665169C (pt) |
| CL (1) | CL2007002909A1 (pt) |
| DE (1) | DE602007007642D1 (pt) |
| DK (1) | DK2074221T3 (pt) |
| ES (1) | ES2346929T3 (pt) |
| IL (2) | IL197782A (pt) |
| MX (1) | MX2009003730A (pt) |
| PT (1) | PT2074221E (pt) |
| RU (1) | RU2460539C2 (pt) |
| WO (1) | WO2008045852A2 (pt) |
| ZA (1) | ZA200902502B (pt) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| EP2385981B1 (en) * | 2008-12-18 | 2019-09-04 | Wyeth LLC | Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon |
| WO2010080486A2 (en) | 2008-12-18 | 2010-07-15 | Wyeth Llc | Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight |
| EP3017826A1 (en) | 2009-03-24 | 2016-05-11 | Novartis AG | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
| CN104548082A (zh) | 2009-03-24 | 2015-04-29 | 诺华股份有限公司 | 为脑膜炎球菌因子h结合蛋白添加佐剂 |
| DK2424562T3 (en) | 2009-04-30 | 2015-12-07 | Coley Pharm Group Inc | Pneumococcal vaccine and uses thereof |
| WO2011161653A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
| CN102094053B (zh) * | 2010-11-26 | 2013-01-16 | 兰州生物制品研究所有限责任公司 | 肺炎链球菌c多糖的纯化方法 |
| CN103533954B (zh) | 2011-03-02 | 2015-09-09 | 诺华股份有限公司 | 含较低剂量的抗原和/或佐剂的联合疫苗 |
| EP2797624A1 (en) | 2011-12-29 | 2014-11-05 | Novartis AG | Adjuvanted combinations of meningococcal factor h binding proteins |
| WO2013131983A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
| EP2822584A1 (en) | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
| BR112015005056A2 (pt) | 2012-09-06 | 2017-11-21 | Novartis Ag | vacinas de combinação com sorogrupo b meningococcus e d/t/p |
| CA2884241C (en) * | 2012-09-07 | 2018-11-20 | Sk Chemicals Co., Ltd. | Production method for capsular polysaccharide having pneumococcal serotype |
| JP2016502994A (ja) | 2012-12-18 | 2016-02-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ジフテリア及び／又は破傷風から防御するためのコンジュゲート |
| IL312327B2 (en) | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| FI3583947T3 (fi) | 2014-01-21 | 2023-10-12 | Pfizer | Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit |
| BR112016015835B1 (pt) | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| PL3244917T3 (pl) | 2015-01-15 | 2023-07-17 | Pfizer Inc. | Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom |
| CA2983708C (en) | 2015-04-28 | 2023-09-19 | Biological E Limited | Method for separation of protein and other impurities from microbial capsular polysaccharides |
| KR102143534B1 (ko) | 2015-05-04 | 2020-08-12 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| KR20250058066A (ko) | 2015-07-21 | 2025-04-29 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| US10786561B2 (en) | 2015-11-20 | 2020-09-29 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| EP3493837B1 (en) | 2016-08-05 | 2022-08-31 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US11224652B2 (en) | 2016-08-05 | 2022-01-18 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| IL267709B2 (en) | 2016-12-30 | 2025-04-01 | Vaxcyte Inc | Polypeptide-antigen conjugates with unnatural amino acids |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| BR112019014833A2 (pt) | 2017-01-20 | 2020-04-14 | Pfizer | composições imunogênicas para uso em vacinas pneumococais |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| JP7680185B2 (ja) | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強 |
| US10435433B2 (en) | 2017-07-05 | 2019-10-08 | Inventprise, Llc | Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography |
| US10702596B2 (en) | 2017-07-05 | 2020-07-07 | Inventprise, Llc | Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography |
| CN111065387B (zh) | 2017-09-07 | 2023-08-25 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
| US11395849B2 (en) | 2017-09-07 | 2022-07-26 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| EP3720483B1 (en) | 2017-12-06 | 2025-11-19 | Merck Sharp & Dohme LLC | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2019152921A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| BR112020015696A2 (pt) | 2018-02-05 | 2020-12-08 | Sanofi Pasteur, Inc. | Composição de conjugado polissacarídeo-proteína pneumocócico multivalente |
| JP7397000B2 (ja) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法 |
| WO2019212846A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| WO2019212842A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| EP4483896A3 (en) | 2018-07-04 | 2025-04-02 | Vaxcyte, Inc. | Improvements in immunogenic conjugates |
| US20220016229A1 (en) | 2018-12-12 | 2022-01-20 | Pfizer Inc. | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof |
| EP3897705A2 (en) | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| JP2022542316A (ja) | 2019-07-31 | 2022-09-30 | サノフィ パスツール インコーポレイテッド | 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法 |
| US12473379B2 (en) * | 2019-09-06 | 2025-11-18 | Serum Institute Of India Private Limited | Method for obtaining purified bacterial polysaccharides |
| EP4038079A4 (en) * | 2019-10-01 | 2023-11-01 | Glycom A/S | SEPARATION OF NEUTRAL OLIGOSACCHARIDES FROM A FERMENTATION BROTH |
| CN115362177A (zh) * | 2020-02-21 | 2022-11-18 | 辉瑞公司 | 糖类的纯化 |
| WO2021229604A1 (en) * | 2020-05-14 | 2021-11-18 | Serum Institute Of India Private Limited | Methods for simultaneous fragmentation and purification of bacterial polysaccharides |
| EP4203995A1 (en) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| US20230383324A1 (en) * | 2020-10-22 | 2023-11-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US20230405137A1 (en) | 2020-11-10 | 2023-12-21 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CA3218544A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| JP7714690B2 (ja) | 2021-05-28 | 2025-07-29 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| JP2025508749A (ja) | 2022-01-13 | 2025-04-10 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| US20260130987A1 (en) | 2022-10-19 | 2026-05-14 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| EP4622665A2 (en) | 2022-11-22 | 2025-10-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN120513083A (zh) | 2022-12-01 | 2025-08-19 | 辉瑞大药厂 | 肺炎链球菌缀合物疫苗制剂 |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2024246082A1 (en) | 2023-03-30 | 2025-10-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PE20252779A1 (es) | 2023-04-14 | 2025-12-22 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121263203A (zh) | 2023-05-19 | 2026-01-02 | 葛兰素史克生物有限公司 | 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法 |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4413057A (en) * | 1980-04-14 | 1983-11-01 | Merck & Co., Inc. | Group B streptococcal capsular polysaccharides |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| CA2366152A1 (en) * | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Streptococcus pneumoniae vaccine |
| KR20080081978A (ko) * | 2000-03-16 | 2008-09-10 | 더 칠드런스 호스피탈 오브 필라델피아 | 폐렴구균의 캡슐 다당류 생산의 조절 방법 |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US20050220777A1 (en) * | 2003-11-21 | 2005-10-06 | Stefan Roos | Selection of lactic acid bacteria enhancing the immune response against Streptococcus pneumoniae |
| PL1866342T3 (pl) | 2005-04-08 | 2019-04-30 | Wyeth Llc | Oddzielanie zanieczyszczeń od polisacharydu Streptococcus pneumoniae przez manipulację pH |
| CA2636983A1 (en) * | 2006-01-13 | 2007-07-26 | Baxter International Inc. | Method for purifying polysaccharides |
-
2007
- 2007-10-09 CA CA2665169A patent/CA2665169C/en active Active
- 2007-10-09 BR BRPI0717834A patent/BRPI0717834B8/pt active IP Right Grant
- 2007-10-09 PT PT07843999T patent/PT2074221E/pt unknown
- 2007-10-09 WO PCT/US2007/080768 patent/WO2008045852A2/en not_active Ceased
- 2007-10-09 MX MX2009003730A patent/MX2009003730A/es active IP Right Grant
- 2007-10-09 DK DK07843999.9T patent/DK2074221T3/da active
- 2007-10-09 RU RU2009112453/10A patent/RU2460539C2/ru active
- 2007-10-09 KR KR1020097009585A patent/KR101467002B1/ko active Active
- 2007-10-09 CL CL200702909A patent/CL2007002909A1/es unknown
- 2007-10-09 BR BR122019021950A patent/BR122019021950B8/pt active IP Right Grant
- 2007-10-09 AT AT07843999T patent/ATE473289T1/de active
- 2007-10-09 CN CN2007800378009A patent/CN101522906B/zh active Active
- 2007-10-09 ES ES07843999T patent/ES2346929T3/es active Active
- 2007-10-09 DE DE602007007642T patent/DE602007007642D1/de active Active
- 2007-10-09 US US11/869,206 patent/US7659090B2/en active Active
- 2007-10-09 CN CN201210083999.1A patent/CN102648979B/zh active Active
- 2007-10-09 JP JP2009532526A patent/JP5260531B2/ja active Active
- 2007-10-09 AU AU2007307800A patent/AU2007307800C1/en active Active
-
2009
- 2009-03-24 IL IL197782A patent/IL197782A/en active IP Right Grant
- 2009-04-09 ZA ZA200902502A patent/ZA200902502B/xx unknown
-
2014
- 2014-07-31 IL IL233893A patent/IL233893A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0717834A2 (pt) | Purificação de polissacarídeos tipo 3 de streptococcus pneumoniae | |
| MX2019005911A (es) | Anticuerpos anti_cd137 novedosos y usos de estos. | |
| NI200900172A (es) | Proceso abreviado de purificación para la producción de polisacaridos capsulares streptococcus pneumaniae. | |
| EA201070987A1 (ru) | Очищенные гибридные белки иммуноглобулина и способы их очищения | |
| MX2007001638A (es) | Proteinas de fusion del dominio de unión. | |
| ATE537188T1 (de) | Serumalbuminbindende proteine | |
| WO2007095506A8 (en) | Oligosaccharide modification and labeling of proteins | |
| MX348154B (es) | Anticuerpos de enlace a il-1-beta y fragmentos de los mismos. | |
| WO2008074840A3 (en) | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders | |
| WO2008023247A3 (en) | Matrix attachment regions (mars) for increasing transcription and uses thereof | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| MX2008009886A (es) | Anticuerpos que enlazan par-2. | |
| ATE543810T1 (de) | Hemmer des 5-lipoxygenase aktivierenden proteins (flap) | |
| WO2006087637A3 (en) | Anti her2/neu antibody | |
| TN2009000442A1 (en) | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 | |
| WO2007052168A3 (en) | Fed batch culture methods for streptococci | |
| WO2009043922A3 (en) | Extracellular targets for alzheimer's disease | |
| WO2009155102A3 (en) | Method for derivatization of proteins using hydrostatic pressure | |
| WO2008033556A3 (en) | High pressure treatment of proteins for reduced immunogenicity | |
| IL218442A0 (en) | Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma | |
| CN102040667B (zh) | 海参多糖中蛋白的生物脱除方法 | |
| CN106244570A (zh) | 一种核糖核酸酶及其衍生物和/或变体及其应用 | |
| WO2024182451A3 (en) | Multivalent anti-spike protein binding molecules and uses thereof | |
| TW200745337A (en) | Modified process | |
| PL410472A1 (pl) | Sposób wytwarzania hydrolizatu białkowego metodą enzymatyczną |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |